Airlines brace for further chaos, even as eight Democratic senators broke ranks with their party to back a deal that could end the shutdown.
Category: Regulation and Deregulation of Industry
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
France Blocks Orders From Shein as It Expands Its Crackdown
Customs officials were ordered to inspect more than 200,000 packages entering the country at Charles de Gaulle Airport.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
-
Key Justices Cast a Skeptical Eye on Trump’s Tariffs
The Supreme Court is considering whether the president acted legally when he used a 1977 emergency statute to impose tariffs on scores of countries.
-
Trump Aides Raise Recession Fears, and Point Fingers at the Fed
Treasury Secretary Scott Bessent said some sectors were in a recession as he argued for more interest rate cuts.
-
The Workers Left Out of Trump’s Drug-Manufacturing Renaissance
President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines.
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
F.D.A. Drug Unit Chief Is Placed on Leave, and Cites a ‘Toxic’ Environment
The official, Dr. George F. Tidmarsh, a top regulator at the agency, said disagreements over a new program to rapidly approve medications had caused tensions with agency officials.